• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    InMode Reports Second Quarter 2023 Financial Results; Record Quarterly Revenue of $136.1M Represents 20% Year-Over-Year Growth

    7/27/23 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email

    YOKNEAM, Israel, July 27, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2023.

    INMODE Logo

    Second Quarter 2023 Highlights:

    • Record quarterly revenue of $136.1 million, an increase of 20% compared to the second quarter of 2022. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 81% of quarterly revenues, while 9% came from InMode's hands-free platforms and 10% from InMode's traditional laser and non-invasive RF platforms.
    • Record GAAP net income of $55.7 million, compared to $44.0 million in the second quarter of 2022; *non-GAAP net income of $62.2 million, compared to $50.4 million in the second quarter of 2022.
    • Record GAAP diluted earnings per share of $0.65, compared to $0.52 in the second quarter of 2022; *non-GAAP diluted earnings per share of $0.72, compared to $0.59 in the second quarter of 2022.
    • Record quarterly revenues from consumables and service of $21.6 million, an increase of 44% compared to the second quarter of 2022.
    • Total cash position of $629.4 million as of June 30, 2023, including cash and cash equivalents, marketable securities, and short-term bank deposits.

    U.S. GAAP Results

    (U.S. dollars in thousands, except for per share data)



    Q2 2023

    Q2 2022

    Revenues

    $136,081

    $113,547

    Gross Margins

    84 %

    83 %

    Net Income

    $55,729

    $44,048

    Earnings per Diluted Share

    $0.65

    $0.52

    *Non-GAAP Results

    (U.S. dollars in thousands, except for per share data)



    Q2 2023

    Q2 2022

    Gross Margins

    84 %

    84 %

    Net Income

    $62,234

    $50,401

    Earnings per Diluted Share

    $0.72

    $0.59

    *Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation adjustments.

    Management Comments

    "We are pleased to report a record quarter with revenue of $136.1 million, as sales from our platforms and disposables were the strongest they've ever been," said Moshe Mizrahy, Chairman and Chief Executive Officer. "Our commitment to innovation supports our growth and leads to a solid brand recognition within the aesthetics industry."

    Shakil Lakhani, President of InMode North America, commented, "Once again, we saw an increase in consumable and platform sales in the second quarter. Revenue from consumables and service for the second quarter grew nearly 44% year-over-year and reached a record level."

    "InMode's Envision platform, which offers a full periorbital treatment, continued to perform well in Q2, as we gained market traction stemming from the soft launch in Canada last year," said Dr. Spero Theodorou, Chief Medical Officer.

    Second Quarter 2023 Financial Results

    Total revenues for the second quarter of 2023 reached $136.1 million, an increase of 20% compared to the second quarter of 2022.

    "We are happy to deliver another strong quarter, with record revenue and EPS in Q2," said Yair Malca, Chief Financial Officer. "Our significant international sales growth reached a record level of $49.5 million, and along with the expanded use of InMode's platforms, we were able to increase our full-year guidance."

    GAAP gross margin for the second quarter of 2023 was 84% compared to a gross margin of 83% 2022. *Non-GAAP gross margin for the second quarter of 2023 and 2022 was 84%.

    GAAP operating margin for the second quarter of 2023 was 42%, compared to an operating margin of 43% in the second quarter of 2022. *Non-GAAP operating margin for the second quarter of 2023 was 47% compared to 49% for the second quarter of 2022. This slight decrease was primarily attributable to higher sales and marketing expenses, mainly because of the addition of new sales representatives, higher travel expenses, as well as investment in direct-to-consumer advertising campaigns and hosting in-person events to support the company's growth projections.

    InMode reported GAAP net income of $55.7 million, or $0.65 per diluted share, in the second quarter of 2023, compared to $44.0 million, or $0.52 per diluted share, in the second quarter of 2022. On a *non-GAAP basis, InMode reported net income of $62.2 million, or $0.72 per diluted share, in the second quarter of 2023, compared to $50.4 million, or $0.59 per diluted share, in the second quarter of 2022.

    2023 Financial Outlook

    Management provided an outlook for the full year of 2023 ending December 31, 2023. Based on current estimates, management expects:

    • Revenue between $530 million and $540 million
    • *Non-GAAP gross margin between 83% and 85%
    • *Non-GAAP income from operations between $238 million and $243 million
    • *Non-GAAP earnings per diluted share between $2.62 and $2.66

    This outlook is not a guarantee of future performance and stockholders should not rely on such forward-looking statements. See "Forward-Looking Statements" for additional information.

    *Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation adjustments.

    Use of Non-GAAP Financial Measures

    In addition to InMode's operating results presented in accordance with GAAP, this release contains certain non-GAAP financial measures including non-GAAP net income, non-GAAP earnings per diluted share, and non-GAAP operating margin. Because these measures are used in InMode's internal analysis of financial and operating performance, management believes they provide investors with greater transparency of its view of InMode's economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode's GAAP operating results, allows investors to more effectively evaluate and compare InMode's performance to that of its peers, although InMode's presentation of its non-GAAP measures may not be strictly comparable to the similarly titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release.

    Conference Call Information

    Mr. Moshe Mizrahy, Chairman and Chief Executive Officer, Dr. Michael Kreindel, Co-Founder and Chief Technology Officer, Mr. Yair Malca, Chief Financial Officer, Mr. Shakil Lakhani, President of North America, and Dr. Spero Theodorou, Chief Medical Officer, will host a conference call today, July 27, 2023, at 8:30 a.m. Eastern Time to discuss the second quarter 2023 financial results.

    The Company encourages participants to pre-register for the conference call using the following link: 

    https://dpregister.com/sreg/10180180/f9c680d37c.

    Callers will receive a unique dial-in number upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

    For callers who opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.

    U.S. Toll-Free Dial-in Number: 1-833-316-0562

    Israel Toll- Free Dial-in Number: 1-80-921-2373

    International Dial-in Number: 1-412-317-5736

    Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=hAHIxqyf

    At:

    8:30 a.m. Eastern Time

    5:30 a.m. Pacific Time

    3:30 p.m. Israel Time

    The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from July 27, 2023, at 12 p.m. Eastern Time to Aug 10, 2023, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers: 

    Replay Dial-in U.S TOLL-FREE: 1-877-344-7529

    Replay Dial-in Canada TOLL-FREE: 855-669-9658

    Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088

    Replay Pin Number: 3384563

    To access the replay using an international dial-in number, please select the link below:

    https://services.choruscall.com/ccforms/replay.html

    A replay of the conference call will also be available for 90 days on InMode's website at https://inmodemd.com/investors/.

    About InMode

    InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

    Forward-Looking Statements

    The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the future performance described above under the heading titled "2023 Financial Outlook." Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including with respect to the impact of the COVID-19 global outbreak. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 14, 2023, as well as risk factors relating to the COVID-19 global outbreak and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

    Company Contact:

    Yair Malca

    Chief Financial Officer

    Phone: (949) 305-0108

    Email: [email protected]

    Investor Relations Contact:

    Miri Segal

    MS-IR LLC

    Phone: (917) 607-8654

    Email: [email protected]

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    Three months ended

    June 30,

    Six months ended

    June 30,



    2023

    2022

    2023

    2022



    REVENUES

    136,081

    113,547

    242,155

    199,468



    COST OF REVENUES

    22,054

    18,946

    40,308

    33,718



    GROSS PROFIT

    114,027

    94,601

    201,847

    165,750



    OPERATING EXPENSES:











    Research and development

    3,567

    3,183

    6,669

    5,998



    Sales and marketing

    51,059

    39,653

    92,772

    70,502



    General and administrative

    2,392

    2,562

    4,400

    5,039



    TOTAL OPERATING EXPENSES

    57,018

    45,398

    103,841

    81,539



    INCOME FROM OPERATIONS

    57,009

    49,203

    98,006

    84,211



    Finance income (expense), net

    4,445

    (918)

    7,734

    (539)



    INCOME BEFORE TAXES

    61,454

    48,285

    105,740

    83,672



    INCOME TAXES

    5,725

    4,237

    9,506

    8,649



    NET INCOME

    55,729

    44,048

    96,234

    75,023















    NET INCOME PER SHARE:











    Basic

    0.67

    0.54

    1.16

    0.91



    Diluted

    0.65

    0.52

    1.12

    0.88



    WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN

     COMPUTATION OF NET INCOME PER SHARE (in thousands)











    Basic

    83,405

    82,216

    83,280

    82,590



    Diluted

    85,650

    84,663

    85,579

    85,236



     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    June 30,

    2023

    December 31,

    2022

    Assets





    CURRENT ASSETS:





    Cash and cash equivalents

    159,855

    97,540

    Marketable securities

    400,464

    374,589

    Short-term bank deposits

    69,094

    75,254

    Accounts receivable, net of allowance for doubtful accounts

    32,568

    26,997

    Other receivables

    18,656

    15,094

    Inventories

    38,568

    39,897

    TOTAL CURRENT ASSETS

    719,205

    629,371

    NON-CURRENT ASSETS:





    Accounts receivable, net of allowance for doubtful accounts

    3,871

    3,973

    Deferred income tax asset, net

    2,350

    3,094

    Operating lease right-of-use assets

    5,595

    5,073

    Property and equipment, net

    2,463

    2,298

    Other investments

    600

    600

    TOTAL NON-CURRENT ASSETS

    14,879

    15,038

    TOTAL ASSETS

    734,084

    644,409

    Liabilities and shareholders' equity





    CURRENT LIABILITIES:





    Accounts payable

    13,295

    16,242

    Contract liabilities

    11,098

    13,798

    Other liabilities

    36,340

    51,980

    TOTAL CURRENT LIABILITIES

    60,733

    82,020

    NON-CURRENT LIABILITIES:





    Contract liabilities

    3,038

    3,959

    Other liabilities

    533

    303

    Operating lease liabilities

    3,622

    3,509

    TOTAL NON-CURRENT LIABILITIES

    7,193

    7,771

    TOTAL LIABILITIES

    67,926

    89,791







    TOTAL SHAREHOLDERS' EQUITY

    666,158

    554,618

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

    734,084

    644,409

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)







    Three months ended

    June 30,

    Six months ended

    June 30,



    2023

    2022

    2023

    2022



    CASH FLOWS FROM OPERATING ACTIVITIES:











    Net income

    55,729

    44,048

    96,234

    75,023



    Adjustments required to reconcile net income to net cash provided by operating activities:











    Depreciation and amortization

    184

    155

    372

    293



    Share-based compensation expenses

    6,505

    6,353

    10,714

    9,447



    Allowance for doubtful accounts

    261

    142

    239

    352



    Loss on marketable securities, net

    -

    23

    -

    37



    Finance expenses (income), net

    (1,197)

    851

    (2,709)

    941



    Deferred income taxes, net

    43

    169

    62

    147



    Changes in operating assets and liabilities:











    Increase in accounts receivable

    (7,949)

    (8,247)

    (5,708)

    (4,294)



    Increase in other receivables

    (3,791)

    (398)

    (4,020)

    (1,593)



    Decrease (increase) in inventories

    2,243

    (4,660)

    1,329

    (8,734)



    Increase (decrease) in accounts payable

    1,308

    2,292

    (2,947)

    3,054



    Increase (decrease) in other liabilities

    7,211

    4,105

    (15,832)

    (770)



    Increase (decrease) in contract liabilities

    (7,547)

    2,148

    (3,621)

    4,931



    Net cash provided by operating activities

    53,000

    46,981

    74,113

    78,834



    CASH FLOWS FROM INVESTING ACTIVITIES:











    Investment in short-term deposits

    (100,000)

    (22,500)

    (106,000)

    (45,611)



    Proceeds from short-term deposits

    106,500

    23,000

    112,500

    43,000



    Purchase of fixed assets

    (194)

    (561)

    (535)

    (860)



    Purchase of marketable securities

    (54,190)

    (17,545)

    (172,542)

    (38,754)



    Proceeds from sale of marketable securities

    -

    1,008

    -

    2,002



    Proceeds from maturity of marketable securities

    60,891

    14,224

    152,028

    25,157



    Net cash provided by (used in) investing activities

    13,007

    (2,374)

    (14,549)

    (15,066)



    CASH FLOWS FROM FINANCING ACTIVITIES:











    Repurchase of ordinary shares

    -

    -

    -

    (42,637)



    Exercise of options

    827

    204

    2,500

    365



    Net cash provided by (used in) financing activities

    827

    204

    2,500

    (42,272)



    EFFECT OF EXCHANGE RATE CHANGES ON CASH

    60

    (1,077)

    251

    (1,228)



    NET INCREASE IN CASH AND CASH EQUIVALENTS

    66,894

    43,734

    62,315

    20,268















    CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

    92,961

    44,670

    97,540

    68,136



    CASH AND CASH EQUIVALENTS AT END OF PERIOD

    159,855

    88,404

    159,855

    88,404



     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    Three months ended June 30,

    Six months ended June 30,

    2023

    2022

    2023

    2022

    Revenues by Category:



































    Capital Equipment revenues - United States

    73,828

    54 %

    62,960

    56 %

    123,579

    51 %

    107,720

    54 %

    Capital Equipment revenues - International

    40,635

    30 %

    35,560

    31 %

    77,008

    32 %

    62,743

    31 %

    Total Capital Equipment revenues

    114,463

    84 %

    98,520

    87 %

    200,587

    83 %

    170,463

    85 %

    Consumables and service revenues

    21,618

    16 %

    15,027

    13 %

    41,568

    17 %

    29,005

    15 %

    Total Net Revenue

    136,081

    100 %

    113,547

    100 %

    242,155

    100 %

    199,468

    100 %



















     

     



    Three months ended June 30,

    Six months ended June 30,

    2023

    2022

    2023

    2022



    %

    %

    %

    %



    United States

    International

    Total

    United States

    International

    Total

    United States

    International

    Total

    United States

    International

    Total

    Revenues by Technology:

























    Minimal-Invasive

    86

    73

    81

    84

    74

    80

    88

    74

    83

    84

    72

    79

    Hands-Free

    11

    6

    9

    14

    5

    11

    10

    6

    8

    13

    6

    11

    Non-Invasive

    3

    21

    10

    2

    21

    9

    2

    20

    9

    3

    22

    10



    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

     

     

    INMODE LTD.





















    RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF





















    INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME 





















    (U.S. dollars in thousands, except for per share data)





















    (Unaudited)













































    Three months ended June 30, 2023

    Three months ended June 30, 2022









    GAAP

    Share Based

    Compensation

    Non-GAAP

    GAAP

    Share Based

    Compensation

    Non-GAAP









    REVENUES

    136,081

    -

    136,081

    113,547

    -

    113,547









    COST OF REVENUES

    22,054

    (547)

    21,507

    18,946

    (496)

    18,450









    GROSS PROFIT

    114,027

    547

    114,574

    94,601

    496

    95,097









    OPERATING EXPENSES:





















    Research and development

    3,567

    (757)

    2,810

    3,183

    (866)

    2,317









    Sales and marketing

    51,059

    (4,731)

    46,328

    39,653

    (4,459)

    35,194









    General and administrative

    2,392

    (470)

    1,922

    2,562

    (532)

    2,030









    TOTAL OPERATING

    EXPENSES

    57,018

    (5,958)

    51,060

    45,398

    (5,857)

    39,541









    INCOME FROM OPERATIONS

    57,009

    6,505

    63,514

    49,203

    6,353

    55,556









    Finance income (expense), net

    4,445

    -

    4,445

    (918)

    -

    (918)









    INCOME BEFORE TAXES

    61,454

    6,505

    67,959

    48,285

    6,353

    54,638









    INCOME TAXES

    5,725

    -

    5,725

    4,237

    -

    4,237









    NET INCOME

    55,729

    6,505

    62,234

    44,048

    6,353

    50,401































    NET INCOME PER SHARE:





















    Basic

    0.67



    0.75

    0.54



    0.61









    Diluted

    0.65



    0.72

    0.52



    0.59









    WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN

     COMPUTATION OF NET INCOME PER SHARE (in thousands)





















    Basic

    83,405



    83,405

    82,216



    82,216









    Diluted

    85,650



    86,243

    84,663



    85,366









     

     

    INMODE LTD.

    RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF

     INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME 

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)



    Six months ended June 30, 2023

    Six months ended June 30, 2022

    GAAP

    Share Based

    Compensation

    Non-GAAP

    GAAP

    Share Based

    Compensation

    Non-GAAP

    REVENUES

    242,155

    -

    242,155

    199,468

    -

    199,468

    COST OF REVENUES

    40,308

    (901)

    39,407

    33,718

    (810)

    32,908

    GROSS PROFIT

    201,847

    901

    202,748

    165,750

    810

    166,560

    OPERATING EXPENSES:













    Research and development

    6,669

    (1,258)

    5,411

    5,998

    (1,391)

    4,607

    Sales and marketing

    92,772

    (7,769)

    85,003

    70,502

    (6,354)

    64,148

    General and administrative

    4,400

    (786)

    3,614

    5,039

    (892)

    4,147

    TOTAL OPERATING

    EXPENSES

    103,841

    (9,813)

    94,028

    81,539

    (8,637)

    72,902

    INCOME FROM OPERATIONS

    98,006

    10,714

    108,720

    84,211

    9,447

    93,658

    Finance income (expense),net

    7,734

    -

    7,734

    (539)

    -

    (539)

    INCOME BEFORE TAXES

    105,740

    10,714

    116,454

    83,672

    9,447

    93,119

    INCOME TAXES

    9,506

    -

    9,506

    8,649

    -

    8,649

    NET INCOME

    96,234

    10,714

    106,948

    75,023

    9,447

    84,470















    NET INCOME PER

    SHARE:













    Basic

    1.16



    1.28

    0.91



    1.02

    Diluted

    1.12



    1.24

    0.88



    0.98

    WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN

     COMPUTATION OF NET INCOME PER SHARE (in thousands)













    Basic

    83,280



    83,280

    82,590



    82,590

    Diluted

    85,579



    86,062

    85,236



    85,786

     

     

    Logo: https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/inmode-reports-second-quarter-2023-financial-results-record-quarterly-revenue-of-136-1m-represents-20-year-over-year-growth-301886825.html

    SOURCE InMode LTD

    Get the next $INMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    SEC Filings

    View All

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    3/13/26 7:00:09 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    2/23/26 7:00:19 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-8 filed by InMode Ltd.

    S-8 - InMode Ltd. (0001742692) (Filer)

    2/10/26 7:38:08 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InMode downgraded by BTIG Research

    BTIG Research downgraded InMode from Buy to Neutral

    4/29/25 8:06:22 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

    4/28/25 1:56:11 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on InMode with a new price target

    BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

    10/17/24 7:41:34 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InMode to Present at the 25th Annual Needham Virtual Healthcare Conference

    YOKNEAM, Israel, March 24, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026. The fireside chat, moderated by Michael Matson, Senior Equity Analyst, is scheduled for 11:00 am Eastern Time on Monday, April 13, and a live webcast of the presentation can be accessed here. InMode will also hold virtual one-on-one investor meetings

    3/24/26 8:30:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Announces New Share Repurchase Program

    YOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a new share repurchase program for up to approximately 10% of the Company's total shares outstanding, representing approximately 6.38 million ordinary shares. In 2025, the Company repurchased approximately $127.4 million of its outstanding ordinary shares through share repurchase programs. Despite a challenging macroeconomic environment, the Company continues to generate strong cash fl

    3/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Present at Upcoming Investor Conferences

    YOKNEAM, Israel, Feb. 26, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in March: Barclays 28th Annual Global Healthcare ConferencePresenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Matt Miksic, Senior Equity Analyst, and one-on-one meetingsLocation: Miami, FLWhen: Wednesday, March 11 at 12:30 pm ETA live webcast of the presentation can be accessed here.Oppenheimer 36th Annual Healthcare MedTech & Services ConferencePresenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial OfficerFormat: Virt

    2/26/26 8:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by InMode Ltd.

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:09:10 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by InMode Ltd.

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:06:52 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Mizrahy Moshe

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:08:06 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Leadership Updates

    Live Leadership Updates

    View All

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Financials

    Live finance-specific insights

    View All

    InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million

    YOKNEAM, Israel, Feb. 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights: Quarterly GAAP revenues of $103.9 million, compared to $97.9 million in the fourth quarter of 2024.Quarterly revenues from consumables and service of $21.5 million, an increase of 8% compared to the fourth quarter of 2024.GAAP operation income of $26 million, *non-GAAP operation income of $28.5 million.Total cash position of $555.3 million as of December 31, 2025, including cash and cash equivalents, marketable securiti

    2/10/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026, Expects Q4 Revenue Between $103.6M-$103.8M

    Conference call to be held on Tuesday, February 10, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Jan. 8, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year of 2025 before the Nasdaq market opens on Tuesday, February 10, 2026. InMode is currently finalizing its financial results for the fourth quarter and full year of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and ot

    1/8/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins

    YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.Total cash position of $532.3 million as of September 30, 2025, incl

    11/5/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:31:18 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:25:40 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by InMode Ltd.

    SC 13G - InMode Ltd. (0001742692) (Subject)

    2/6/24 9:36:39 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care